To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Pathology: Vacancies
Thursday 20th June 2019

Asked by: Sarah Wollaston (Liberal Democrat - Totnes)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what the level of vacancy is in histopathology departments.

Answered by Stephen Hammond

NHS Improvement publishes vacancy data for three staff groups; doctors, nurses and ‘other staff’. These vacancy statistics are published for England and at the regional level of North, Midlands and East, London and South.

They do not specifically produce vacancy data for histopathology departments or any vacancy data for each National Health Service hospital or trust.

NHS Digital published the latest NHS Improvement vacancy data which can be found in the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/nhs-vacancies-survey/february-2015---march-2019-provisional-experimental-statistics


Written Question
Genetics: Screening
Thursday 20th June 2019

Asked by: Sarah Wollaston (Liberal Democrat - Totnes)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many patients have received whole genome sequencing through the NHS; and how many of those patients had a type of blood cancer.

Answered by Caroline Dinenage

As part of the NHS Long Term Plan, the National Health Service has committed to sequencing 500,000 whole genomes by 2023/24.

During 2019, the NHS will begin to offer whole genome sequencing (WGS) as part of clinical care for:

- Seriously ill children likely to have a rare genetic disorder;

- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and

- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS – children with cancer, sarcoma and Acute Myeloid Leukaemia.

As the price of whole genome sequencing falls and the evidence improves, we envisage that it will be extended to more conditions and therefore more patients.


Written Question
Genetics: Screening
Thursday 20th June 2019

Asked by: Sarah Wollaston (Liberal Democrat - Totnes)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many patients he estimates will benefit from whole genome sequencing in (a) 2019 and (b) each of the next five years.

Answered by Caroline Dinenage

As part of the NHS Long Term Plan, the National Health Service has committed to sequencing 500,000 whole genomes by 2023/24.

During 2019, the NHS will begin to offer whole genome sequencing (WGS) as part of clinical care for:

- Seriously ill children likely to have a rare genetic disorder;

- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and

- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS – children with cancer, sarcoma and Acute Myeloid Leukaemia.

As the price of whole genome sequencing falls and the evidence improves, we envisage that it will be extended to more conditions and therefore more patients.


Written Question
Genetics: Screening
Thursday 20th June 2019

Asked by: Sarah Wollaston (Liberal Democrat - Totnes)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the NHS Genomic Medicine Service will begin performing whole genome sequencing.

Answered by Caroline Dinenage

As part of the NHS Long Term Plan, the National Health Service has committed to sequencing 500,000 whole genomes by 2023/24.

During 2019, the NHS will begin to offer whole genome sequencing (WGS) as part of clinical care for:

- Seriously ill children likely to have a rare genetic disorder;

- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and

- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS – children with cancer, sarcoma and Acute Myeloid Leukaemia.

As the price of whole genome sequencing falls and the evidence improves, we envisage that it will be extended to more conditions and therefore more patients.


Speech in Commons Chamber - Tue 18 Jun 2019
Oral Answers to Questions

"Sharing information saves lives when it comes to suicide prevention, but families are too often unnecessarily excluded because clinicians may be unaware of or do not follow the consensus statement guidance on seeking consent and sharing information in the patient’s best interests. I thank the Minister for meeting me and …..."
Sarah Wollaston - View Speech

View all Sarah Wollaston (LD - Totnes) contributions to the debate on: Oral Answers to Questions

Speech in Westminster Hall - Mon 10 Jun 2019
Cystic Fibrosis Drugs: Orkambi

"I thank my constituent, Cathy Meredith, who started this petition. I also thank Oli Rayner and the many others living with cystic fibrosis who, sadly, cannot be in the Public Gallery with us today because cystic fibrosis is such a curiously isolating condition—those suffering from it cannot be in the …..."
Sarah Wollaston - View Speech

View all Sarah Wollaston (LD - Totnes) contributions to the debate on: Cystic Fibrosis Drugs: Orkambi

Speech in Westminster Hall - Mon 10 Jun 2019
Cystic Fibrosis Drugs: Orkambi

"The Minister referred to the importance of Vertex engaging with NICE. Does she share my concern that when I wrote to Vertex and NICE about the failure to make progress, Vertex assured me that it had contributed “substantial new evidence” on the three products in question, yet I subsequently heard …..."
Sarah Wollaston - View Speech

View all Sarah Wollaston (LD - Totnes) contributions to the debate on: Cystic Fibrosis Drugs: Orkambi

Speech in Commons Chamber - Thu 23 May 2019
Whorlton Hall

"Too many people are ending up in terrible institutional care hundreds of miles from home for the want of much more appropriate community care, including social care. The Minister has spoken about not wanting to delay the publication of reports, but she will know that the delay to the social …..."
Sarah Wollaston - View Speech

View all Sarah Wollaston (LD - Totnes) contributions to the debate on: Whorlton Hall

Written Question
Social Prescribing
Thursday 23rd May 2019

Asked by: Sarah Wollaston (Liberal Democrat - Totnes)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what his Department's policy is on social prescribing.

Answered by Caroline Dinenage

‘Prevention is better than cure’, published by the Department in November 2018, highlighted the important role social prescribing can play in reducing people’s isolation and improving levels of activity.

As set out in the NHS Long Term Plan, NHS England has committed to deliver at least £4.5 billion of new investment in primary medical and community health services over the next five years. Part of this investment will support the recruitment of over 1,000 trained social prescribing link workers - in place by the end of 2020/21 rising further by 2023/24, with the aim that over 900,000 people are able to be referred to social prescribing schemes by then.

The Prevention document and the Long Term Plan can be found at the following links:

www.gov.uk/government/publications/prevention-is-better-than-cure-our-vision-to-help-you-live-well-for-longer

www.longtermplan.nhs.uk/publication/nhs-long-term-plan/


Written Question
Preventive Medicine
Wednesday 8th May 2019

Asked by: Sarah Wollaston (Liberal Democrat - Totnes)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the Prevention is better than cure vision published by his Department in November 2018, whether the forthcoming prevention Green Paper will include oral health.

Answered by Seema Kennedy

We are considering a number of policy options for the prevention green paper and will be mindful of oral health opportunities.